Shop vibrant dresses, standout activewear, and iconic Lilly Pulitzer prints for 60% off—only for 48 hours. Grab your Lilly Pop-Up Sale favorites now before sizes and styles start selling out fast.

Your closet is about to be in bloom! For two days only, Lilly Pulitzer is blossoming with discounts on its cheery dresses, ...

Results of the Lilly-funded study provide a promising first look. Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

There were churchgoing conservatives and Silicon Valley technologists, parents of five and parents of nine, edgelords in leather jackets and women in Lilly Pulitzer, all sharing a common concern ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Eli Lilly and Company, which already markets weight-loss and diabetes drugs that must be injected, is a step closer to introducing a once-daily pill for the same conditions. On April 17 ...